Cite
Bailey DB, Berry-Kravis E, Wheeler A, et al. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. J Neurodev Disord. 2015;8:1doi: 10.1186/s11689-015-9134-5.
Bailey, D. B., Berry-Kravis, E., Wheeler, A., Raspa, M., Merrien, F., Ricart, J., Koumaras, B., Rosenkranz, G., Tomlinson, M., von Raison, F., & Apostol, G. (2016). Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. Journal of neurodevelopmental disorders, 81. https://doi.org/10.1186/s11689-015-9134-5
Bailey, Donald B, et al. "Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study." Journal of neurodevelopmental disorders vol. 8 (2016): 1. doi: https://doi.org/10.1186/s11689-015-9134-5
Bailey DB, Berry-Kravis E, Wheeler A, Raspa M, Merrien F, Ricart J, Koumaras B, Rosenkranz G, Tomlinson M, von Raison F, Apostol G. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. J Neurodev Disord. 2016;8:1. doi: 10.1186/s11689-015-9134-5. Epub 2015 Dec 15. PMID: 26855682; PMCID: PMC4743124.
Copy
Download .nbib